Pharmacokinetics and Efficacy of a Ketorolac-loaded Ocular Coil in New Zealand White Rabbits

Overview

Journal Drug Deliv

Specialty Pharmacology

Date 2021 Feb 17

PMID 33594935

Citations 5

Authors

Christian J F Bertens

Marlies Gijs

Aylvin A J Dias

Frank J H M van den Biggelaar

Arkasubhra Ghosh

Swaminathan Sethu

Rudy M M A Nuijts

Affiliations

Soon will be listed here.

Abstract

Eye drops are considered standard practice for the delivery of ocular drugs. However, low patient compliance and low drug levels compromise its effectiveness. Our group developed a ketorolac-loaded ocular coil for sustained drug delivery up to 28 days. The aim of this study was to gain insight into the pharmacokinetics and efficacy of the ocular coil. The pharmacokinetics of the ketorolac-loaded ocular coil versus eye drops were tested in New Zealand White rabbits by repetitive sampling for 28 days. Efficacy of the ocular coil was also tested in New Zealand White rabbits. Ocular inflammation was induced where after the ocular coil was inserted, or eye drops, or no treatment was provided. The total protein concentration and cytokine levels were measured in tears, aqueous humor, and plasma at 4 h, 8 h, 24 h, 4 d, 7 d, 14 d, 21 d, and 28 d. Four h after inserting the ocular coil in the eye, ketorolac levels in aqueous humor and plasma were higher in the ocular coil group than in the eye drop group. Ketorolac released from the ocular coil could be detected up to 28 d in tears, up to 4 d in aqueous humor and up to 24 h in plasma. After inducing inflammation, both the ocular coil and eye drops were able to suppress prostaglandin E, TNFα and IL-6 levels in aqueous humor and plasma as compared to the group that received no treatment. To conclude, the ocular coil facilitated a sustained release of the drug and showed similar therapeutic benefit in suppressing post-operative inflammation as eye drops.

Citing Articles

Investigating recent advances in pharmacotherapy for acute and chronic ocular pain post-cataract surgery.

Donthineni P, Munger W, Galor A Expert Opin Pharmacother. 2024; 25(16):2107-2113.

PMID: 39441206 PMC: 11573624. DOI: 10.1080/14656566.2024.2421323.

Innovative Strategies for Drug Delivery to the Ocular Posterior Segment.

Gabai A, Zeppieri M, Finocchio L, Salati C Pharmaceutics. 2023; 15(7).

PMID: 37514050 PMC: 10385847. DOI: 10.3390/pharmaceutics15071862.

Innovation in the Development of Synthetic and Natural Ocular Drug Delivery Systems for Eye Diseases Treatment: Focusing on Drug-Loaded Ocular Inserts, Contacts, and Intraocular Lenses.

Pelusi L, Mandatori D, Mastropasqua L, Agnifili L, Allegretti M, Nubile M Pharmaceutics. 2023; 15(2).

PMID: 36839947 PMC: 9961328. DOI: 10.3390/pharmaceutics15020625.

Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma.

Zhao Y, Huang C, Zhang Z, Hong J, Xu J, Sun X Drug Deliv. 2022; 29(1):613-623.

PMID: 35174743 PMC: 8856066. DOI: 10.1080/10717544.2022.2039806.

Repeatability, reproducibility, and agreement of three tonometers for measuring intraocular pressure in rabbits.

Bertens C, van Mechelen R, Berendschot T, Gijs M, Wolters J, Gorgels T Sci Rep. 2021; 11(1):19217.

PMID: 34584185 PMC: 8478901. DOI: 10.1038/s41598-021-98762-7.

References

Pijls R, Hanssen H, Nuijts R, Koole L . Flexible coils with a drug-releasing hydrophilic coating: a new platform for controlled delivery of drugs to the eye?. Biomed Mater Eng. 2004; 14(4):383-93. View

Pijls R, Cruysberg L, Nuijts R, Dias A, Koole L . Capacity and tolerance of a new device for ocular drug delivery. Int J Pharm. 2007; 341(1-2):152-61. DOI: 10.1016/j.ijpharm.2007.04.007. View

Walters T, Raizman M, Ernest P, Gayton J, Lehmann R . In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007; 33(9):1539-45. DOI: 10.1016/j.jcrs.2007.05.015. View

Pijls R, Hanssen H, Nuijts R, Daube G, Koole L . In vivo tolerance and kinetics of a novel ocular drug delivery device. J Control Release. 2007; 116(2):e47-9. DOI: 10.1016/j.jconrel.2006.09.043. View

Bertens C, Zhang S, Erckens R, Biggelaar F, Berendschot T, Webers C . Confocal Raman spectroscopy: Evaluation of a non-invasive technique for the detection of topically applied ketorolac tromethamine in vitro and in vivo. Int J Pharm. 2019; 570:118641. DOI: 10.1016/j.ijpharm.2019.118641. View

Bertens C, Gijs M, Biggelaar F, Nuijts R . Topical drug delivery devices: A review. Exp Eye Res. 2018; 168:149-160. DOI: 10.1016/j.exer.2018.01.010. View

Pijls R, Sonderkamp T, Daube G, Krebber R, Hanssen H, Nuijts R . Studies on a new device for drug delivery to the eye. Eur J Pharm Biopharm. 2005; 59(2):283-8. DOI: 10.1016/j.ejpb.2004.08.011. View

Visco D, Bedi R . Effect of intracameral phenylephrine 1.0%-ketorolac 0.3% on postoperative cystoid macular edema, iritis, pain, and photophobia after cataract surgery. J Cataract Refract Surg. 2020; 46(6):867-872. DOI: 10.1097/j.jcrs.0000000000000193. View

Bucci Jr F, Waterbury L . A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification. Curr Med Res Opin. 2011; 27(12):2235-9. DOI: 10.1185/03007995.2011.626018. View

10.

Bucci Jr F, Waterbury L . Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing. Adv Ther. 2009; 26(6):645-50. DOI: 10.1007/s12325-009-0042-5. View

11.

Urtti A, Salminen L . Minimizing systemic absorption of topically administered ophthalmic drugs. Surv Ophthalmol. 1993; 37(6):435-56. DOI: 10.1016/0039-6257(93)90141-s. View

12.

Bertens C, Martino C, van Osch M, Lataster A, Dias A, Biggelaar F . Design of the ocular coil, a new device for non-invasive drug delivery. Eur J Pharm Biopharm. 2020; 150:120-130. DOI: 10.1016/j.ejpb.2020.03.010. View

13.

Unger W, COLE D, Hammond B . Disruption of the blood--aqueous barrier following paracentesis in the rabbit. Exp Eye Res. 1975; 20(3):255-70. DOI: 10.1016/0014-4835(75)90139-6. View

14.

Urtti A . Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006; 58(11):1131-5. DOI: 10.1016/j.addr.2006.07.027. View

15.

Eaton A, Gordon G, Konowal A, Allen A, Allen M, Sgarlata A . A novel eye drop application monitor to assess patient compliance with a prescribed regimen: a pilot study. Eye (Lond). 2015; 29(10):1383-91. PMC: 4815690. DOI: 10.1038/eye.2015.155. View

16.

Sharma N, Acharya S, Nair A, Matalia J, Shetty R, Ghosh A . Dopamine levels in human tear fluid. Indian J Ophthalmol. 2018; 67(1):38-41. PMC: 6324103. DOI: 10.4103/ijo.IJO_568_18. View

17.

Motulsky H, Brown R . Detecting outliers when fitting data with nonlinear regression - a new method based on robust nonlinear regression and the false discovery rate. BMC Bioinformatics. 2006; 7:123. PMC: 1472692. DOI: 10.1186/1471-2105-7-123. View

18.

Olthoff C, Hoevenaars J, van den Borne B, Webers C, Schouten J . Prevalence and determinants of non-adherence to topical hypotensive treatment in Dutch glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 2008; 247(2):235-43. DOI: 10.1007/s00417-008-0944-y. View

19.

Mohindroo C, Ichhpujani P, Kumar S . How 'Drug Aware' are our Glaucoma Patients?. J Curr Glaucoma Pract. 2016; 9(2):33-7. PMC: 4750024. DOI: 10.5005/jp-journals-10008-1181. View

20.

Lee S, Geroski D, Prausnitz M, Edelhauser H . Drug delivery through the sclera: effects of thickness, hydration, and sustained release systems. Exp Eye Res. 2004; 78(3):599-607. DOI: 10.1016/s0014-4835(03)00211-2. View